Drug Type Small molecule drug |
Synonyms CB-1089, EB-1089 |
Target |
Action agonists |
Mechanism VDR agonists(Vitamin D receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC30H46O3 |
InChIKeyLVLLALCJVJNGQQ-SEODYNFXSA-N |
CAS Registry134404-52-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatocellular Carcinoma | Phase 3 | Canada | 01 Nov 1999 | |
Hepatocellular Carcinoma | Phase 3 | France | 01 Nov 1999 | |
Hepatocellular Carcinoma | Phase 3 | Italy | 01 Nov 1999 | |
Hepatocellular Carcinoma | Phase 3 | Spain | 01 Nov 1999 | |
Hepatocellular Carcinoma | Phase 3 | United Kingdom | 01 Nov 1999 | |
Liver Cancer | Phase 3 | European Union | - | |
Pancreatic Cancer | Phase 2 | United Kingdom | - | |
Prostatic Cancer | Phase 1 | United States | - | |
Advanced Hepatocellular Carcinoma | Clinical | Canada | 01 Sep 1999 | |
Advanced Hepatocellular Carcinoma | Clinical | France | 01 Sep 1999 |
Not Applicable | 10 | kcqwkkvzqd(eoymdxzsxp) = aftmcfcjix ibuhpidijz (hjmqkknrnj ) View more | Positive | 30 Apr 2019 | |||
Control group (CG) | uoqzhuqlhn(afpibyqrxb) = idewjwpofx fvmgtnfcem (uqmjuidelq, 0.4) View more |